Pneumological Acute Coronary Syndrom (ACS) Phenotyping Aachen

Acute Coronary Syndrom Clinical Trial

— PAPA  

Official title:

Pneumological Phenotyping of Acute Coronary Syndrom (ACS) Patients Concerning Concomitant Chronic Obstructive Pulmonary Disease (COPD)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02587481
• Other study ID #: 15-057
• Status: Completed
• Phase: N/A
• First received: October 15, 2015
• Last updated: November 17, 2017
• Start date: November 2015
• Est. completion date: May 2017

Study information

• Verified date: November 2017
• Source: RWTH Aachen University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

In this open, monocentric, observational study acute coronary syndrom (ACS) patients will be characterized by pneumological examination concerning a concomitant chronic obstructive pulmonary disease (COPD). Often COPD coexists with ACS; therefore ACS patients benefit either from prevention or potential therapy of chronic hypoxia.

Description:

In this study patients with either non ST-segment-elevation myocardial infarction (NSTEMI) or ST-segment-elevation myocardial infarction (STEMI) will be included. After amnesis patients will undergo blood withdrawal, blood-gas analysis and examinations concerning pulmonary function (Bodyplethysmography). In addition to routine blood withdrawal for differential blood count, 9 ml blood sample is takenfor molecular analysis of relevant prognostic chronic obstructive pulmonary disease (COPD)-blood based biomarkers, an for establishing a library of biomaterial in form of a biobank.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: May 2017
• Est. primary completion date: May 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Written declaration of consent

• Patients with acute myocardial infarct which can be either non ST-segment-elevation myocardial infarct (NSTEMI) or ST-segment-elevation myocardial infarct (STEMI), in both cases exaggeration of cardiac ischaemic markers

Exclusion Criteria:

• Patients not fulfilling the incluson criterias or:

• Pregnant or breastfeeding women

• Participation in other studies

• Persons in depency from the sponsor or working with the sponsor

• Persons without mental ability or capacity to understand and follow the instructions of the investigator

Related Conditions & MeSH terms

• Acute Coronary Syndrom
• Chronic Obstructive Pulmonary Syndrom
• Lung Diseases, Obstructive
• Pulmonary Disease, Chronic Obstructive

Locations

Country	Name	City	State
Germany	Amrei Pelzer	Aachen	NRW

Sponsors (1)

Lead Sponsor	Collaborator
RWTH Aachen University

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of patients with Acute Coronary Syndrom (ACS) and concomitant Chronic Obstructive Pulmonary Disease (COPD)		During 1-2 hours (at time of examination)
Secondary	Molecular analysis of relevant blood based chronic obstructive pulmonary disease (COPD) biomarkers		An average of 1 day